Using an antibody raised against amino acids 371–441 in the SEMA7A protein sequence, which will recognize all isoforms of SEMA7A due to sequence homology, we compared SEMA7A expression with multiple breast cancer clinical characteristics that are known prognostic indicators across all 113 cases. Here, SEMA7A is linked to breast carcinoma.